Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2022

<br /> Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2022<br />

PR Newswire


STATESVILLE, N.C.

,

March 9, 2022

/PRNewswire/ — Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended

January 31, 2022

.


Fiscal Year 2022 Third Quarter Results:

Sales during the third quarter of fiscal year 2022 were

$40,633,000

, an increase compared to sales of

$33,339,000

from the prior year third quarter. Kewaunee’s third quarter was negatively impacted by increased COVID-19 related disruptions, a previously disclosed cyber attack, ongoing supply chain issues, labor shortages, and elevated inflation. The impact of higher raw material costs in the third quarter, net of surcharges, was

$424,000

when compared to the prior year period. The profit impact, to domestic operations, of the cyber attack in the period was

$1,131,000

. Finally, the Company experienced other one-time costs in the amount of

$325,000

related to the Company’s previously announced decision to exit certain markets where the Company had historically sold products directly, and professional services related to ongoing financing related activities.

Overall, these negative factors resulted in a pre-tax loss for the quarter of

$887,000

compared to a pre-tax loss of

$718,000

for the prior year period. Kewaunee recorded a net loss of

$1,319,000

compared to net earnings of

$81,000

for the prior year period due to a tax benefit being recorded in the prior period which did not occur in the most recent period. EBITDA

1

for the quarter was

($117,000)

compared to

($17,000)

for the prior year period. Diluted loss per share was

($0.47)

, as compared to diluted earnings per share of

$0.03

in the prior year third quarter.

The Company’s order backlog was

$138

.1 million on

January 31, 2022

, increasing from

$103

.0 million at

January 31, 2021

, and

$114

.5 million at

April 30, 2021

. Also being announced today, the Company’s International segment has been awarded a

$17.3 million

contract for laboratory furniture and equipment by Dangote Oil Refinery Company Limited (hereinafter “Dangote Oil”), located in

Lagos, Nigeria

(

https://www.dangote.com//

). This award was not included in the above reported order backlog amounts and will be reflected in the Company’s order backlog when it reports earnings for the fourth quarter of the Company’s 2022 fiscal year.



Domestic Segment


– Domestic sales for the quarter were

$29,531,000

, an increase of 17.8% from sales of

$25,066,000

in the prior year period. The increase in sales was principally from higher raw material costs passed along in the form of surcharges. Domestic segment net loss was

$305,000

compared to net loss of

$184,000

in the prior year period. Domestic segment EBITDA was

$347,000

compared to

$800,000

for the prior year period.



International Segment


– International sales for the quarter were

$11,102,000

, an increase of 34.2% from sales of

$8,273,000

in the prior year period as activity across the international markets remained strong. International segment net income was

$573,000

compared to

$499,000

in the prior year period. International segment EBITDA was

$874,000

compared to

$695,000

for the prior year period.



Corporate Segment


– Corporate segment pre-tax net loss was

$1,501,000

for the quarter, as compared to

$1,613,000

in the prior year period. Corporate segment EBITDA for the quarter was

($1,338,000)

, a favorable improvement of 11.5% from corporate segment EBITDA of

($1,512,000)

for the prior year period. The primary driver of the improved EBITDA was the favorable impact from pension accounting because of the recovery of the plan assets at fiscal year-end 2021 when compared to fiscal year-end 2020.

Total cash on hand on

January 31, 2022

was

$5,502,000

, as compared to

$5,731,000

at

April 30, 2021

. Working capital was

$21,412,000

, as compared to

$28,510,000

at the end of the third quarter last year and

$26,276,000

at

April 30, 2021

. Short-term debt was

$8,962,000

on

January 31, 2022

, as compared to

$6,828,000

at

April 30, 2021

, and long-term debt was

$329,000

on

January 31, 2022

as compared to

$112,000

at

April 30, 2021

. The Company’s debt-to-equity ratio on

January 31, 2022

was 0.48-to-1, as compared to 0.39-to-1 at April 30, 2021.

“Kewaunee announced a significant shift in its commercial strategy during the quarter whereby Kewaunee would no longer be selling directly in certain territories where dealer coverage has historically been insufficient,” said

Thomas D. Hull III

, Kewaunee’s President and Chief Executive Officer. “Kewaunee announced in

December 2021

that updated dealer agreements had been executed with Nycom and ISEC, two of the premier specialty sub-contractors in the industry. Kewaunee’s greatest opportunity to drive sustained profitability and shareholder value will come from further improving the performance of the Company’s manufacturing capabilities. This change allows us to simplify our business, focus solely on being a world class manufacturer, and continue serving our dealers and distribution partners with excellence.”

“This strategic change, as well as the continued progress in strengthening our backlog, positions the Company well to capitalize on future investments made in the pharmaceutical, biotechnology, health care, higher education, and the other markets we serve. While the third quarter was indeed a challenge on multiple fronts, Kewaunee’s Associates continue to overcome the persistent headwinds that have existed for some time because of COVID-19 and the myriad of other external economic challenges that continue to impact our industry. Kewaunee is well positioned, and we will continue to make investments in our capacity to capitalize on future opportunities.”



1

EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.



EBITDA and Segment EBITDA Reconciliation



Quarter Ended January 31, 2021



Domestic



International



Corporate



Consolidated


Net Earnings (Loss)


$                    (184)


$                     499


$                    (234)


$                        81


Add/(Less):


Interest Expense




1


104


105


Interest Income




(49)




(49)


Income Taxes


390


176


(1,379)


(813)


Depreciation and Amortization


594


68


(3)


659


EBITDA


$                     800


$                     695


$                 (1,512)


$                      (17)



Quarter Ended January 31, 2022



Domestic



International



Corporate



Consolidated


Net Earnings (Loss)


$                    (305)


$                     573


$                 (1,587)


$                 (1,319)


Add/(Less):


Interest Expense




8


150


158


Interest Income




(47)


(4)


(51)


Income Taxes


50


264


85


399


Depreciation and Amortization


602


76


18


696


EBITDA


$                     347


$                     874


$                 (1,338)


$                    (117)



Year to Date January 31, 2021



Domestic



International



Corporate



Consolidated


Net Earnings (Loss)


$                     977


$                  1,088


$                 (2,762)


$                    (697)


Add/(Less):


Interest Expense




2


308


310


Interest Income




(154)


(2)


(156)


Income Taxes


817


503


(2,309)


(989)


Depreciation and Amortization


1,800


196


9


2,005


EBITDA


$                  3,594


$                  1,635


$                 (4,756)


$                     473



Year to Date January 31, 2022



Domestic



International



Corporate



Consolidated


Net Earnings (Loss)


$                 (2,609)


$                  1,313


$                 (4,468)


$                 (5,764)


Add/(Less):


Interest Expense




17


379


396


Interest Income




(138)


(6)


(144)


Income Taxes


50


710


85


845


Depreciation and Amortization


1,825


213


54


2,092


EBITDA


$                    (734)


$                  2,115


$                 (3,956)


$                 (2,575)


About Non-GAAP Measures

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. We believe EBITDA and Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization, which can vary significantly between companies depending upon many factors. EBITDA and Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA and Segment EBITDA can vary among companies. The amounts included in the EBITDA and Segment EBITDA calculations, however, are derived from amounts included in the historical statements of operations. EBITDA and Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company’s operating performance, or as an alternative to operating cash flows as a measure of liquidity.


About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company’s corporate headquarters are located in

Statesville, North Carolina

. Sales offices are located in

the United States

,

India

,

Saudi Arabia

, and

Singapore

. Three manufacturing facilities are located in

Statesville

serving the domestic and international markets, and one manufacturing facility is located in

Bangalore, India

serving the local, Asian, and African markets. Kewaunee Scientific’s website is located at

Home




.


This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: competitive and general economic conditions and the ongoing impact of the COVID-19 pandemic, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, natural disasters and other Force Majeure events; and the ultimate impact on the Company of the cyber attack suffered on

November 5, 2021

. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended

April 30, 2021

, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at


www.kewaunee.com


and on the SEC website at


www.sec.gov


. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:


Donald T. Gardner III


704/871-3274



Kewaunee Scientific Corporation



Condensed Consolidated Statements of Operations



(Unaudited)



($ and shares in thousands, except per share amounts)



Three Months Ended



January 31,



Nine Months Ended



January 31,



2022



2021



2022



2021


Net sales



$       40,633


$       33,339



$     119,157


$     108,762


Cost of products sold



35,011


27,685



104,264


90,832


Gross profit



5,622


5,654



14,893


17,930


Operating expenses



6,490


6,030



19,742


18,593


Operating loss



(868)


(376)



(4,849)


(663)


Pension income (expense)



88


(288)



266


(865)


Other income, net



51


51



149


171


Interest expense



(158)


(105)



(396)


(310)


Loss before income taxes



(887)


(718)



(4,830)


(1,667)


Income tax expense (benefit)



399


(813)



845


(989)


Net (loss) earnings



(1,286)


95



(5,675)


(678)


Less: Net earnings attributable to the non-controlling interest



33


14



89


19


Net (loss) earnings attributable to Kewaunee Scientific Corporation



$        (1,319)


$               81



$        (5,764)


$            (697)


Net (loss) earnings per share attributable to Kewaunee Scientific

Corporation stockholders


Basic



$          (0.47)


$            0.03



$          (2.07)


$          (0.25)


Diluted



$          (0.47)


$            0.03



$          (2.07)


$          (0.25)


Weighted average number of common shares outstanding


Basic



2,790


2,762



2,785


2,759


Diluted



2,790


2,789



2,785


2,759



Kewaunee Scientific Corporation



Condensed Consolidated Balance Sheets



($ in thousands)



January 31,

2022



April 30,


2021




(Unaudited)




Assets



Cash and cash equivalents



$             4,697



$             5,206


Restricted cash



805



525


Receivables, less allowances



35,053



32,882


Inventories



19,947



16,517


Income tax receivable



638



955


Prepaid expenses and other current assets



7,780



4,372


Total Current Assets



68,920



60,457


Net Property, Plant and Equipment



15,345



15,982


Right of use assets



8,006



9,279


Other assets



3,415



3,666


Total Assets



$           95,686



$           89,384




Liabilities and Stockholders’ Equity



Short-term borrowings



$             8,962



$             6,828


Current portion of lease obligations



1,486



1,369


Accounts payable



27,415



16,780


Other Current Liabilities



9,645



9,204


Total Current Liabilities



47,508



34,181


Long-term portion of lease obligations



6,803



7,951


Other non-current liabilities



5,195



5,765


Total Liabilities



59,506



47,897


Kewaunee Scientific Corporation Equity



35,847



41,241


Non-controlling interest



333



246


Total Stockholders’ Equity



36,180



41,487


Total Liabilities and Stockholders’ Equity



$           95,686



$           89,384

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-third-quarter-of-fiscal-year-2022-301499592.html

SOURCE Kewaunee Scientific Corporation